Economic model to examine the cost-effectiveness of FlowOx home therapy compared to standard care in patients with peripheral artery disease.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
06
2020
accepted:
17
12
2020
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
8
5
2021
Statut:
epublish
Résumé
Critical limb ischaemia is a severe stage of lower limb peripheral artery disease which can lead to tissue loss, gangrene, amputation and death. FlowOx™ therapy is a novel negative-pressure chamber system intended for home use to increase blood flow, reduce pain and improve wound healing for patients with peripheral artery disease and critical limb ischaemia. A Markov model was constructed to assess the relative cost-effectiveness of FlowOx™ therapy compared to standard care in lower limb peripheral artery disease patients with intermittent claudication or critical limb ischaemia. The model used data from two European trials of FlowOx™ therapy and published evidence on disease progression. From an NHS analysis perspective, various FlowOx™ therapy scenarios were modelled by adjusting the dose of FlowOx™ therapy and the amount of other care received alongside FlowOx™ therapy, in comparison to standard care. In the base case analysis, consisting of FlowOx™ therapy plus nominal care, the cost estimates were £12,704 for a single dose of FlowOx™ therapy per annum as compared with £15,523 for standard care. FlowOx™ therapy patients gained 0.27 additional quality adjusted life years compared to standard care patients. This equated to a dominant incremental cost-effectiveness ratio per QALY gained. At the NICE threshold WTP of £20,000 and £30,000 per QALY gained, FlowOx™ therapy in addition to standard care had a 0.80 and 1.00 probability of being cost-effectiveness respectively. FlowOx™ therapy delivered as a single annual dose may be a cost-effective treatment for peripheral artery disease. FlowOx™ therapy improved health outcomes and reduced treatment costs in this modelled cohort. The effectiveness and cost-effectiveness of FlowOx™ therapy is susceptible to disease severity, adherence, dose and treatment cost. Research assessing the impact of FlowOx™ therapy on NHS resource use is needed in order to provide a definitive economic evaluation.
Sections du résumé
BACKGROUND
Critical limb ischaemia is a severe stage of lower limb peripheral artery disease which can lead to tissue loss, gangrene, amputation and death. FlowOx™ therapy is a novel negative-pressure chamber system intended for home use to increase blood flow, reduce pain and improve wound healing for patients with peripheral artery disease and critical limb ischaemia.
METHODS
A Markov model was constructed to assess the relative cost-effectiveness of FlowOx™ therapy compared to standard care in lower limb peripheral artery disease patients with intermittent claudication or critical limb ischaemia. The model used data from two European trials of FlowOx™ therapy and published evidence on disease progression. From an NHS analysis perspective, various FlowOx™ therapy scenarios were modelled by adjusting the dose of FlowOx™ therapy and the amount of other care received alongside FlowOx™ therapy, in comparison to standard care.
RESULTS
In the base case analysis, consisting of FlowOx™ therapy plus nominal care, the cost estimates were £12,704 for a single dose of FlowOx™ therapy per annum as compared with £15,523 for standard care. FlowOx™ therapy patients gained 0.27 additional quality adjusted life years compared to standard care patients. This equated to a dominant incremental cost-effectiveness ratio per QALY gained. At the NICE threshold WTP of £20,000 and £30,000 per QALY gained, FlowOx™ therapy in addition to standard care had a 0.80 and 1.00 probability of being cost-effectiveness respectively.
CONCLUSIONS
FlowOx™ therapy delivered as a single annual dose may be a cost-effective treatment for peripheral artery disease. FlowOx™ therapy improved health outcomes and reduced treatment costs in this modelled cohort. The effectiveness and cost-effectiveness of FlowOx™ therapy is susceptible to disease severity, adherence, dose and treatment cost. Research assessing the impact of FlowOx™ therapy on NHS resource use is needed in order to provide a definitive economic evaluation.
Identifiants
pubmed: 33444396
doi: 10.1371/journal.pone.0244851
pii: PONE-D-20-16557
pmc: PMC7808667
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244851Déclaration de conflit d'intérêts
HH is employed by Otivio AS with funding from The Research Council of Norway (grant no. 285758). Otivio AS has the commercial rights to the INP technology used in this study. The authors alone are responsible for the content and writing of the paper. We adhere fully to PLOS ONE policies on sharing data and materials.
Références
BMJ Open. 2017 Nov 3;7(11):e016030
pubmed: 29101132
Eur J Vasc Endovasc Surg. 2018 Apr;55(4):529-536
pubmed: 29478910
Diabet Med. 2019 Aug;36(8):995-1002
pubmed: 31004370
J Plast Reconstr Aesthet Surg. 2012 Mar;65(3):395-8
pubmed: 21868297
World J Plast Surg. 2016 Sep;5(3):265-273
pubmed: 27853690
Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158
pubmed: 15361314
Angiology. 2016 Oct;67(9):860-9
pubmed: 26764367
Physiol Rep. 2016 Oct;4(20):
pubmed: 27798353
Diabet Med. 2014 Dec;31(12):1498-504
pubmed: 24984759
BMJ. 1990 Jan 27;300(6719):230-5
pubmed: 2106931
Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75
pubmed: 17140820
Lancet. 2003 May 3;361(9368):1545-51
pubmed: 12737879
J Vasc Surg. 2012 Aug;56(2):361-71
pubmed: 22560307
Pharmacoeconomics. 2018 Jul;36(7):745-758
pubmed: 29779120
Physiol Rep. 2016 Sep;4(17):
pubmed: 27630148
Qual Life Res. 2019 Aug;28(8):2257-2279
pubmed: 30929124
Diabetes Care. 2006 Mar;29(3):566-70
pubmed: 16505507
Syst Rev. 2015 May 23;4:74
pubmed: 26001384
BMJ. 2000 Mar 25;320(7238):854-7
pubmed: 10731185
Qual Life Res. 2013 Sep;22(7):1717-27
pubmed: 23184421
J Vasc Surg. 2014 May;59(5):1291-9
pubmed: 24393280
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Tech Vasc Interv Radiol. 2016 Jun;19(2):91-5
pubmed: 27423989
Vasc Health Risk Manag. 2009;5:833-41
pubmed: 19851521
Health Econ. 2005 May;14(5):487-96
pubmed: 15497198
Pharmacoeconomics. 2016 Apr;34(4):349-61
pubmed: 26660529
BMJ. 2018 Feb 1;360:j5842
pubmed: 29419394
Diabetes Care. 2016 Nov;39(11):2058-2064
pubmed: 27612499
Eur J Vasc Endovasc Surg. 2018 Aug;56(2):271-281
pubmed: 29653901
PLoS One. 2017 Aug 28;12(8):e0182081
pubmed: 28846690
Lancet. 2013 Oct 19;382(9901):1329-40
pubmed: 23915883
J Rehabil Res Dev. 2007;44(5):631-6
pubmed: 17943674
Circ Cardiovasc Interv. 2016 Feb;9(2):e001946
pubmed: 26858079
J Foot Ankle Surg. 2017 Nov - Dec;56(6):1218-1222
pubmed: 28765052
Int J Technol Assess Health Care. 2013 Apr;29(2):117-22
pubmed: 23587340
World J Plast Surg. 2018 Jan;7(1):58-66
pubmed: 29651393
Med Devices (Auckl). 2009;2:57-65
pubmed: 22915915
Cochrane Database Syst Rev. 2016 Sep 14;9:CD010680
pubmed: 27623758
BMC Med Res Methodol. 2012 Nov 07;12:168
pubmed: 23134698
Pharmacoeconomics. 1998 Apr;13(4):397-409
pubmed: 10178664
Trials. 2017 Dec 28;18(1):628
pubmed: 29284523
Br J Nurs. 2000 Oct;9(19 Suppl):S6, S8, S10 passim
pubmed: 12271239
BMJ. 2012 Aug 08;345:e4947
pubmed: 22875949
Atherosclerosis. 2004 Jan;172(1):95-105
pubmed: 14709362